课题基金 / 基金详情

Mechanisms of REST-mediated immunosuppression in cancer

Mechanisms of REST-mediated immunosuppression in cancer
REST 介导的癌症免疫抑制机制
批准号:
10749289
负责人:
Daniel E Michaud
金额:
$6.91万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2025-07-31
关键词:
AgitationAntigensBiological AssayBreast Cancer CellCD8-Positive T-LymphocytesCSF1R geneCancer EtiologyCell secretionCellsCellular ImmunityCessation of lifeCharacteristicsCoculture TechniquesCytometryDataFlow CytometryGene Expression ProfileGenesGoalsGrantImmuneImmune responseImmunofluorescence ImmunologicImmunologistImmunosuppressionImmunotherapeutic agentImmunotherapyIn VitroInfiltrationIntrinsic factorKDR geneKnock-outLinkLymphangiogenesisLymphaticLymphatic EndotheliumLymphocyteLymphocyte ActivationLymphocyte FunctionLymphocyte SuppressionLymphocytic InfiltrateMacrophageMalignant NeoplasmsMammary NeoplasmsMediatingMigration AssayModelingMusMyelogenousNeurosecretory SystemsOutcomePathway AnalysisPatientsPeriodicityPhenotypePopulationPositioning AttributePrognosisProliferatingRNARNA analysisRefractoryRegulationResearchResearch ProposalsResistanceRestRoleSignal TransductionSolid NeoplasmT-LymphocyteTechnical ExpertiseTestingThe Cancer Genome AtlasTherapeuticTrainingTranscription RepressorTumor PromotionTumor-Infiltrating LymphocytesTumor-associated macrophagesUnited StatesVascular Endothelial Growth FactorsWomanWritinganti-PD-1biomarker discoverybiomarker identificationcancer cellcareerchemokinecytokinecytotoxicityeffector T cellfunctional lossimmune cell infiltrateimmune checkpoint blockadeimmunoregulationimprovedin vivoin vivo Modelloss of functionmalignant breast neoplasmmolecular subtypesnano-stringnovelprognostic of survivalprogrammed cell death ligand 1recruitresponseskillssynergismtargeted treatmenttranscriptometranscriptome sequencingtreatment responsetreatment strategytumortumor growthtumor microenvironmenttumor-immune system interactions

项目摘要

项目成果

Daniel E Michaud的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Abstract Tumor-intrinsic factors in cancer cells modulate the immune milieu to enable prolonged survival and growth of tumors. In breast cancer (BC), the 2nd leading cause of cancer-related deaths in women, molecular subtyping of these factors effectively guides targeted therapies, but does not guide immunotherapy approaches as immune infiltrates vary significantly within each subtype. The presence of tumor-infiltrating lymphocytes (TILs) is highly prognostic for survival and therapeutic benefit in BC, but the tumor-intrinsic factors governing their presence are not well defined. Using TCGA RNA analysis, I have identified loss of function in the transcriptional repressor REST as being a key correlate to reduced lymphocyte infiltration into tumors of multiple BC molecular subtypes. Loss of functional REST in BC (~15-20% of tumors) is associated with poorer prognoses, however, the mechanisms by which loss of REST function modulates the tumor immune microenvironment are not known and may provide novel targets for enhancing therapeutic responses. I recently generated a murine Rest knockout BC line (Rest-less) and my in vivo studies confirmed that Rest-less tumors contain significantly less lymphocytes while also revealing a significant increase in pro-tumor macrophages, a cell population our lab has identified as being key modulators of lymphocyte suppression in BC. Furthermore, my in vitro studies identified lymphangiogenic Vegfc and Vegfd among the most differentially upregulated genes in Rest-less BC cells. Tumor lymphangiogenesis is linked to T cell suppression in solid tumors and may provide a reason for Rest-mediated suppression of lymphocytes. Based on my preliminary data, I hypothesize that lymphocyte suppression in Rest- less tumors is orchestrated by the polarization of tumor-associated macrophages (TAMs) and lymphatic endothelium to a suppressive phenotype. I propose two specific aims to test my hypothesis. In Aim 1, I will determine the role of tumor intrinsic Rest on TAM-mediated lymphocyte suppression using co-culture assays of TAMs from Rest-less tumors together with lymphocytes in vitro and macrophage depletion through anti-CSF-1R treatment in an antigen-specific (GFP; JEDI) Rest-less model in vivo. In Aim 2, I will evaluate how Vegfr3, the receptor for Vegfc and Vegfd, regulates the REST-less tumor microenvironment and responsiveness to immunotherapy. To accomplish this task, I will test anti-Vegfr3 blockade on Rest-less tumors with or without anti- PD1 and comprehensively analyze tumor growth, lymphatic depletion, and immune responses using RNAseq, spectral cytometry, and cyclic immunofluorescence. Our proposed research will provide an understanding of a previously uncharacterized facet of REST-mediated immune suppression in BC and will use novel murine orthotopic models to test strategies that block immune suppressive mechanisms. Ultimately, I anticipate my findings will reveal targetable mechanism(s) to inhibit Rest-mediated immunosuppression in BC and provide a considerable impact on the treatment of REST-less tumors overall.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of B cell specific IL-35 expression in cancer.
Mechanisms of B cell specific IL-35 expression in cancer.
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究